Treatments for childhood anaplastic large cell lymphoma

The following are treatment options for childhood anaplastic large cell lymphoma (ALCL). The healthcare team will suggest treatments based on your child’s health and specific information about the lymphoma. Treatments are often based on the stage.

Treatments for newly diagnosed childhood anaplastic large cell lymphoma

The main treatment for newly diagnosed childhood ALCL is chemotherapy.

Chemotherapy

Chemotherapy is the main treatment for childhood ALCL. Most children receive chemotherapy for 3 to 5 months, but in some treatment centres it may be given for a longer period.

Chemotherapy drugs are given in different combinations based on different treatment plans (protocols). The most common chemotherapy drugs used in combinations for ALCL are:

  • doxorubicin (Adriamycin)
  • cyclophosphamide (Procytox)
  • vincristine (Oncovin)
  • prednisone
  • methotrexate
  • mercaptopurine (Purinethol)
  • cytarabine (Cytosar)
  • dexamethasone (Decadron, Dexasone)
  • etoposide (Vepesid, VP-16)
  • ifosfamide (Ifex)
  • leucovorin (folinic acid)
  • hydrocortisone
  • vinblastine
  • daunorubicin (Cerubidine, daunomycin)
  • asparaginase (Kidrolase)
  • thioguanine (Lanvis)

Intrathecal chemotherapy may be given to prevent spread of ALCL to the brain and spinal cord (called the central nervous system, or CNS) or to treat ALCL that has spread to the CNS. This means that the drugs are given directly into the cerebrospinal fluid (CSF) around the brain and spinal cord. Intrathecal chemotherapy can include 1 to 3 of the following drugs:

  • methotrexate
  • cytarabine
  • hydrocortisone

Treatments for cutaneous anaplastic large cell lymphoma

Sometimes childhood ALCL develops only in the skin. This is called cutaneous ALCL. It may be treated with surgery, radiation therapy or both. Sometimes chemotherapy with low-dose methotrexate is also given.

Treatments for recurrent childhood anaplastic large cell lymphoma

Treatments for recurrent (relapsed) childhood ALCL may include more intense chemotherapy, targeted therapy or an allogeneic or autologous stem cell transplant.

Chemotherapy drugs and combinations used for recurrent ALCL include:

  • ifosfamide, carboplatin (Paraplatin, Paraplatin AQ) and etoposide
  • vinblastine
  • crizotinib (Xalkori)
  • ceritinib (Zykadia)
  • brentuximab vedotin (Adcetris)

Clinical trials

Children with cancer may be treated in a clinical trial. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.

Expert review and references

  • Allen CE, Kamdar KY, Bollard CM, Gross TG . Malignant non-Hodgkin lymphomas in children. Pizzo PA & Poplack DG (eds.). Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia: Wolters Kluwer; 2016: 23: 587-603.
  • American Cancer Society. Treating Non-Hodgkin Lymphoma in Children. 2017.
  • Gross TG & Perkins SL . Malignant non-Hodgkin lymphomas in children. Pizzo, P. A. & Poplack, D. G. (Eds.). Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011: 23:pp. 663-682.
  • Johnston JM. Pediatric Non-Hodgkin Lymphoma Treatment and Management. 2018.
  • National Cancer Institute. Childhood Non-Hodgkin Lymphoma Treatment (PDQ®) Patient Version. 2018.
  • National Cancer Institute. Childhood Non-Hodgkin Lymphoma Treatment (PDQ®) Health Professional Version. 2018.
  • Truong TH, Weitzman, S, Arceci RJ . Non-Hodgkin lymphoma of childhood. Wiernik PH, Goldman JM, Dutcher JP & Kyle RA (eds.). Neoplastic Diseases of the Blood. 5th ed. Springer; 2013: 48: pp. 1049-1072.
  • Woods D, McDonald, L . Non-Hodgkin lymphoma. Baggott C, Fochtman D, Foley GV & Patterson Kelly, K (eds.). Nursing Care of Children and Adolescents with Cancer. 4rd ed. APHON; 2011: 29: pp. 1023-1037.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society